Navigation Links
Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
Date:8/21/2012

(PROVIDENCE, R.I.) For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.

Now, a new National Institutes of Health research grant awarded to Colleen Kelly, M.D., a gastroenterologist with the Center for Women's Gastrointestinal Medicine at the Women's Medicine Collaborative, and co-investigator Lawrence Brandt, M.D., from the Albert Einstein School of Medicine in New York, will test whether an unconventional yet promising treatment known as fecal bacteriotherapy, or fecal transplantation, is an effective therapy for patients with relapsing C. difficile.

While it sounds unpleasant, previous research suggests fecal transplantation, which involves transplanting healthy donor stool into the patient's colon during a colonoscopy, is extremely successful; according to published case studies, the procedure has "cured" relapsing C. difficile in 89 percent of patients without any complications. However, few physicians know about the procedure, which has been around for more than 50 years, and to date there have been no published prospective clinical trials of fecal transplant for C. difficile.

Kelly's research will be the first randomized controlled clinical trial of this procedure as a treatment for relapsing C. difficile.

"Our goal is to clearly demonstrate to both the medical community and health insurers that fecal transplant is an viable, safe, inexpensive, and ultimately curative treatment for patients with relapsing C. difficile," said Kelly. "We hope this research is the first step toward developing standard treatment protocols for this procedure and making it more widely available to the many patients who are suffering from recurring C. difficle."

C. difficile affects tens of thousands of Americans each year, particularly patients in hospitals or long-term care facilities, and typically occurs after a dose of antibiotic medications. It has been increasing in both incidence and severity over the last decade, including otherwise healthy people who aren't hospitalized or taking antibiotics. It causes 14,000 deaths annually, according to the Centers for Disease Control and Prevention.

C. difficile disrupts the balance of the normal, healthy, protective bacterial flora found in the colon. When that happens often following a dose of antibiotics invasive bacteria like C. difficile can grow, proliferate and produce toxins that make patients sick.

Approximately 20 percent of patients have recurring C. difficile that does not respond to antibiotics. Patients who experience one recurrence have a 40 percent risk of further relapse, while those with two or more episodes face a 60 percent relapse risk. While the first relapse is generally treated with a second course of antibiotics, current guidelines recommend a tapering course of an expensive antibiotic known as oral vancomycin following a second recurrence.

During a fecal transplant, healthy donor stool is mixed with saline and infused into the colon during a standard outpatient colonoscopy procedure. The patient identifies the donor usually a family member or close friend ahead of time, and the donor undergoes a rigorous screening process. A stool sample is obtained the morning of the procedure.

Kelly, who is also a clinical assistant professor of medicine at The Warren Alpert Medical School of Brown University, says fecal transplant works because the donor stool contains the healthy bacteria needed to restore and repopulate the patient's colon with what she calls an "army of good bacteria" to keep C. difficle from overgrowing and causing disease.

Kelly and Brandt hope to enroll 48 patients in this randomized study, which will determine if fecal transplantation, using stool from a healthy volunteer donor, provides a cure for relapsing C. difficile infection. Collaborating investigators at the University of Minnesota will analyze the complex bacterial communities in stool collected from patients both before and after transplant, as well as their donors.

"Given the increasing incidence and severity of C. difficile infection, the problem of recurrent disease in a significant number of patients, and the economic burden and drug-resistant infections associated with long term use of oral antibiotics, we need this clinical trial to determine whether fecal transplant is an effective treatment for relapsing infection," said Kelly.


'/>"/>
Contact: Jessica Collins Grimes
jgrimes2@lifespan.org
401-793-7484
Lifespan
Source:Eurekalert

Related medicine news :

1. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
4. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
5. New method may allow personalized clinical trial for cancer therapies
6. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
7. NYU School of Medicine announces new clinical trial for ulcerative colitis
8. Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
9. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
10. 32-country study shows that type 2 diabetes drug is clinically effective for long-term use
11. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star Insurance ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:5/4/2016)... ... ... Dr. Elyson and Dr. Assili, dentist in Northridge , announce that ... a common dental procedure, is performed for many adolescents and young adults today. While ... of complications. By providing wisdom tooth removal surgery at their office, Dr. Elyson and ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Francesca Loparco, Co-Founder ... her life forever with a same-day LASIK procedure at Christenbury Eye Center. ... Dr. Jonathan Christenbury performed her surgery the same day as her in-office consultation and ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in models ... Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries ...
(Date:5/4/2016)... ... May 04, 2016 , ... Warren L. Smith M.D. , There ... UTIs, have plagued people since the beginning of recorded medical history, and in ... every year. It's not just a matter of inconvenience; bladder infections cost us billions ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
(Date:5/3/2016)... May 3, 2016 Pharmaceutical giant ... million to a woman who says its talc-based powder ... Gloria Ristesund $5 million in compensatory damages ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This ... the company. In February, the same court awarded $72 ...
Breaking Medicine Technology: